Pentoxifylline affects cytokine reaction in cardiopulmonary bypass.
No Thumbnail Available
Date
2006
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
BACKGROUND: Cardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations. METHODS: In a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points. RESULTS: TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05). CONCLUSIONS: Our results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass.
Description
Keywords
Cardiopulmonary Bypass , Cytokines , Female , Humans , Male , Middle Aged , Myositis , Pentoxifylline , Platelet Aggregation Inhibitors , Treatment Outcome , antithrombocytic agent , cytokine , pentoxifylline , article , blood , cardiopulmonary bypass , clinical trial , controlled clinical trial , controlled study , female , human , immunology , in vitro study , male , middle aged , myositis , randomized controlled trial , treatment outcome